{"id":"NCT02146430","sponsor":"Daiichi Sankyo","briefTitle":"Treatment of Pain Associated With Fibromyalgia","officialTitle":"A Randomized, Double-Blind, Placebo- and Active-Controlled Study of DS-5565 for Treatment of Pain Associated With Fibromyalgia","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2014-10-27","primaryCompletion":"2016-07-14","completion":"2016-07-14","firstPosted":"2014-05-23","resultsPosted":"2020-11-09","lastUpdate":"2020-11-09"},"enrollment":1293,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"DOUBLE","primaryPurpose":"TREATMENT"},"conditions":["Pain Associated With Fibromyalgia"],"interventions":[{"type":"DRUG","name":"DS-5565","otherNames":["mirogabalin"]},{"type":"DRUG","name":"Pregabalin","otherNames":["Lyrica"]},{"type":"DRUG","name":"Placebo tablet","otherNames":["Placebo matching DS-5565"]},{"type":"DRUG","name":"Placebo capsule","otherNames":["Placebo matching pregabalin"]}],"arms":[{"label":"DS-5565 QD","type":"EXPERIMENTAL"},{"label":"DS-5565 BID","type":"EXPERIMENTAL"},{"label":"Pregabalin","type":"ACTIVE_COMPARATOR"},{"label":"Placebo","type":"PLACEBO_COMPARATOR"}],"summary":"The main objective of this trial is to compare change in weekly average daily pain score (ADPS) from baseline to Week 13 in subjects receiving either dose of DS-5565 versus placebo. Weekly ADPS is based on daily pain scores reported by the participant that best describes his or her worst pain over the previous 24 hours.","primaryOutcome":{"measure":"Change From Baseline in Weekly Average Daily Pain Score (ADPS) at Week 13 in Participants Receiving DS-5565, Pregabalin, Placebo","timeFrame":"Baseline up to Week 13 postdose","effectByArm":[{"arm":"Placebo","deltaMin":-1.66,"sd":0.132},{"arm":"Pregabalin 150 mg BID","deltaMin":-1.9,"sd":0.134},{"arm":"DS-5565 15 mg QD","deltaMin":-1.97,"sd":0.134},{"arm":"DS-5565 15 mg BID","deltaMin":-1.93,"sd":0.136}],"pValues":[{"comp":"OG000 vs OG001","p":"0.1870"},{"comp":"OG000 vs OG002","p":"0.0944"},{"comp":"OG000 vs OG003","p":"0.1391"},{"comp":"OG001 vs OG002","p":"0.7338"},{"comp":"OG001 vs OG003","p":"0.8705"}]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":10,"exclusionCount":16},"locations":{"siteCount":165,"countries":["United States","Canada","Czechia","Denmark","Finland","France","Germany","Netherlands","Norway","Serbia","Sweden"]},"refs":{"pmids":["31284771"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":11,"n":318},"commonTop":["Dizziness","Headache","Weight increased","Nausea","Somnolence"]}}